Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

75.78CHF
10:08am EDT
Change (% chg)

CHF-0.38 (-0.50%)
Prev Close
CHF76.16
Open
CHF76.16
Day's High
CHF76.58
Day's Low
CHF75.70
Volume
1,852,575
Avg. Vol
5,669,368
52-wk High
CHF88.30
52-wk Low
CHF74.22

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.06
Market Cap(Mil.): CHF199,881.20
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.80
Yield (%): 3.68

Financials

  NOVN.S Industry Sector
P/E (TTM): 22.63 28.26 32.60
EPS (TTM): 3.38 -- --
ROI: 7.52 13.20 12.74
ROE: 11.54 14.98 14.66

Novartis receives EU approval for biosimilar Zessly

ZURICH Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases.

1:43am EDT

Novartis receives EU approval for biosimilar Zessly

ZURICH, May 24 Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases.

1:21am EDT

BRIEF-Novartis, Amgen Announce FDA Approval Of Aimovig Treatment For Migraine Prevention

* NOVARTIS AND AMGEN ANNOUNCE FDA APPROVAL OF AIMOVIG™ (ERENUMAB-AOOE), A NOVEL TREATMENT DEVELOPED SPECIFICALLY FOR MIGRAINE PREVENTION

May 17 2018

FDA names drugmakers likely blocking access to branded drug samples

May 17 The U.S. Food and Drug Administration on Thursday named drugmakers including Celgene Corp, Mylan NV, Gilead Sciences and Novartis AG for potentially blocking access to samples of their products to delay generic competition.

May 17 2018

Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

LONDON For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.

May 17 2018

FOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire deal

* Takeda boss to raise bar for pipeline drugs after Shire deal

May 17 2018

Novartis top lawyer exits over Trump attorney deal 'mistake'

ZURICH Novartis's top lawyer quit on Wednesday over a $1.2 million contract he co-signed with U.S. President Donald Trump's personal attorney, a deal the Swiss drugmaker's ex-CEO also said was a mistake. | Video

May 16 2018

UPDATE 4-Novartis top lawyer exits over Trump attorney deal 'mistake'

* CEO highlights pipeline strength, scope for bolt-on M&A (Adds comment from former CEO, recasts)

May 16 2018

Novartis ex-CEO says regrets hiring, not firing Trump lawyer

ZURICH Ex-Novartis Chief Executive Joe Jimenez regrets rushing into a $100,000-per-month consulting contract with U.S. President Donald Trump's personal lawyer but said post-election uncertainty over the administration's healthcare ideas put pressure on the Swiss drugmaker to sign a deal quickly.

May 16 2018

UPDATE 1-Novartis ex-CEO says regrets hiring, not firing Trump lawyer

ZURICH, May 16 Ex-Novartis Chief Executive Joe Jimenez regrets rushing into a $100,000-per-month consulting contract with U.S. President Donald Trump's personal lawyer but said post-election uncertainty over the administration's healthcare ideas put pressure on the Swiss drugmaker to sign a deal quickly. "There should have been more due diligence," Jimenez said in an interview with Reuters on Wednesday.

May 16 2018

Earnings vs. Estimates